ADARx Pharmaceuticals, Inc. (ADRX) Stock
Key stats
- Market cap
- $1.42B
- Price / Earnings ratio
- -19.0x
- EPS (TTM)
- -$6.43
- Volume
- Loading
- 52-week high
- $23.21
- 52-week low
- $12.50
Source: third-party data provider, as of November 13, 2026
Compare with ADRX
Recent news

ADARx Pharmaceuticals raises $446.3 million in upsized US IPO
ADARx Pharmaceuticals raises $446.3 million in upsized US IPO
ADRX

ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO
ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO
ADRX
News tone: automated (AI) classification of the article's content, not a price prediction.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

ADARx Pharmaceuticals raises $446.3 million in upsized US IPO
ADARx Pharmaceuticals raises $446.3 million in upsized US IPO
ADRX

ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO
ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO
ADRX
News tone: automated (AI) classification of the article's content, not a price prediction.
About ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. The company is focused on advancing and expanding its pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs.
Fundamentals
Valuation
Trading
Source: third-party data provider, as of November 13, 2026
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $32.00
- Average
- $35.00
- High
- $38.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +3.0 | -13.0 | -15.6 |



